Alfasigma S.p.A.
Alfasigma S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and Asia. Founded in 2015 through the merger of Alfa Wassermann and Sigma-Tau, the company has quickly established itself as a leader in the development and marketing of prescription medicines, particularly in the fields of gastroenterology, central nervous system disorders, and cardiovascular health. Alfasigma's core products, including innovative treatments and generics, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, such as expanding its global footprint and enhancing its research capabilities. With a strong market position and a focus on patient-centric solutions, Alfasigma continues to make strides in improving health outcomes worldwide.
DitchCarbon Score
How does Alfasigma S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alfasigma S.p.A.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alfasigma S.p.A.'s reported carbon emissions
Alfasigma S.p.A., headquartered in Italy, currently does not report any specific carbon emissions data, as there are no available figures for their emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As a result, there is no information on their scope of emissions (Scope 1, 2, or 3) or any significant achievements in reducing carbon emissions. Without specific data or commitments, it is unclear how Alfasigma S.p.A. is addressing climate change within the pharmaceutical industry context. The absence of emissions data and reduction initiatives suggests that Alfasigma may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alfasigma S.p.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
